Recent Updates
Recently added Catalysts
PTHS Positive Sentiment Score: 75/100

Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Key Takeaway: Pelthos Therapeutics announced that its CEO, Scott Plesha, will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. The event will take place at The Lotte New York Palace in New York City. Institutional investors have the opportunity to meet one-on-one with Mr. Plesha through their Piper Sandler representatives. For those unable to attend in person, a live webcast will be accessible on the company’s website approximately two hours after the chat.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pelthos Therapeutics is participating in a significant healthcare conference.
  • The company's CEO will engage directly with institutional investors.
  • A live webcast will allow broader access to their presentation.

Full Press Release Details

DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that Pelthos’ CEO Scott Plesha will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference (the “Conference”) on December 4, 2025 at 9:30 a.m. Eastern Time at The Lotte New York Palace located at 455 Madison Avenue, New York, NY 10022.
Institutional investors interested in scheduling an in-person one-on-one meeting with Mr. Plesha should contact their Piper Sandler representative.
For those unable to attend the Conference in person, a live webcast of the fireside chat will be available on the News & Events page in the Investors section of the Company’s website at https://pelthos.com and can also be found at https://event.webcasts.com/starthere.jsp?ei=1745427&tp_key=593c737d0a approximately two hours after the fireside chat.
About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.
LifeSci Advisors, LLC
Mike Moyer, Managing Director

Frequently Asked Questions

What event will Pelthos CEO Scott Plesha participate in?

Scott Plesha will join a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.

When is the Piper Sandler Conference taking place?

The Conference is scheduled for December 4, 2025, at 9:30 a.m. Eastern Time.

Where can I watch the Pelthos fireside chat online?

A live webcast will be available on Pelthos’ News & Events page after the chat.

What is Pelthos Therapeutics known for?

Pelthos specializes in innovative therapeutic products for unmet patient needs.

What is ZELSUVMI™ used to treat?

ZELSUVMI™ (berdazimer) gel treats molluscum contagiosum and was FDA approved in 2024.

Last updated: Dec 2, 2025